The murine DOR-1 gene was altered by replacing exon
). These results indicate were mated, and mice homozygous for the altered allele that the DOR-1 locus encodes both of the pharmacologiwere present in offspring (Figure 1c) . Genotyping showed cally defined receptors ␦ 1 and ␦ 2 . Therefore, the different that the ␦-deficient offspring were present in the exproperties of the ␦ 1 and ␦ 2 receptor subtypes must arise pected Mendelian frequency (ϩ/ϩ, 26.2%; ϩ/Ϫ, 49.7%; from this locus and could result from differential postand Ϫ/Ϫ, 24.1%) (n ϭ 370 offspring In situ hybridization of the mRNA encoding all three the brain of DOR-1 KO mice (Figure 2a) , indicating the opioid receptors and the endogenous opioid peptide absence of any detectable DOR-1-derived translation precursor genes PENK, POMC, and prodynorphin (PDYN) product, and was significantly reduced in heterozygous were examined in adult brain ( Figure 2d ). As expected, mice (data not shown).
exon 2 DOR-1 transcripts were absent in the Ϫ/Ϫ mutant ␦ receptor binding in brain membrane fractions from mice, although low residual levels (Ͻ15%ϩ/ϩ) of DOR-1 (ϩ/ϩ), DOR-1 (ϩ/Ϫ), and DOR-1 (Ϫ/Ϫ) mutant direct DOR-1 exon 1 to DOR-1 exon 3 transcripts were mice was analyzed using both the ␦ 1 -preferring ligand characterized by Northern and PCR analysis (Figures 2e  and 2f ). These transcripts do not appear to be translated 3 H-DPDPE and the ␦ 2 -preferring ligand 3 H-deltorphin-2. (Figure 3a) . Spinal deltorphin-2 analgesia was also genes. This effect on only ␦ receptor expression thus provided the opportunity to characterize ␦ receptor funcmarkedly diminished in the KO mice (Figure 3c) , indicating a major contribution of DOR-1 to spinal analgesia. tions in DOR-1 KO mice that retain generally normal expression of many other opioid system components.
However, both DPDPE (Figure 3b ) and deltorphin-2 (Figure 3d) retained their analgesic activity, with no reduction in potency, following supraspinal i.c.v. administraSpinal ␦ Analgesia Is Lost and Supraspinal Analgesia Retained in DOR-1 Mutant Mice tion in the DOR-1 KO mice. Thus, these data indicate that there are analgesic systems for classical ␦ agonists We next explored analgesia in DOR-1 mutant mice. In initial experiments, no differences in baseline tailflick that can be mediated through receptors other than DOR-1. We next assessed the activity of a nonpeptide ␦ anallatencies were observed among the wild-type, heterozygous, and homozygous groups using either the standard gesic, BW373U86 (Chang et al., 1993). Given i.c.v., virtually no analgesic response was elicited in wild-type lamp intensity, with latencies between 2 and 3 s, or a reduced lamp intensity that produced latencies of ‫8ف‬ s mice, as had previously been shown (Wild et al., 1993) . In contrast, robust analgesia was observed in DOR-1 (data not shown). We then explored the action of several ␦ agonists. ␦ receptor-selective peptides, such as KO, with all mice tested not only exhibiting analgesia (Figure 3d ) but also reaching maximal analgesic cut-off DPDPE and deltorphin-2, are effective analgesics both spinally and supraspinally (Heyman et al., 1987, 1988) .
times. When administered i.t., BW373U86 did not elicit DOR-1 KO mice, it was not as effective as in the wildtype animals (Figure 5a ). Similar results were observed when the hot plate test was instead used to monitor analgesia (Figure 5b) . Again, naltrexone reversed the analgesic response in all groups, while naltrindole significantly blocked the response in wild-type mice but not in littermate heterozygous or homozygous mice. Antisense approaches also distinguished the residual supraspinal DPDPE analgesia from that normally elicited in wild-type mice. Thus, a DOR-1 antisense probe targeting exon 3, which had previously been shown to reduce ␦ ligand binding (Standifer et al., 1994) , significantly blocked supraspinal DPDPE analgesia in wild- also indicate that the residual supraspinal DPDPE analgesia seen in the KO animals is due to a receptor other than DOR-1, a conclusion also consistent with the partial, rather than complete, sensitivity of the residual analgesia in either wild-type mice or DOR-1 homozyanalgesia to naltrindole. Moreover, the enhanced activgous mutants, even following a 60 g injection (Figure ity described above of i.c.v. and peripheral BW373U86 3d). Thus, both peptide and nonpeptide ␦ agonists elicit in DOR-1 mutant mice suggests that the absence of analgesia in DOR-1 KOs following i.c.v., but not i.t., ad-DOR-1 increases the sensitivity of this novel secondary ministration. We finally tested the response of wild-type ␦ analgesic system, which can both mediate continued and mutant mice to systemic BW373U86 administration. DPDPE and deltorphin-2 supraspinal analgesia and Given systemically, this compound also had little effect dramatically enhance the efficacy of at least one nonin wild-type mice and elicited a maximal analgesic repeptide ␦ agonist. These observations indicate that nonsponse of only 10% at 30 mg/kg. Heterozygous mice peptide agonists, such as BW373U86, likely act predomwere more sensitive, with 30% responding, while homoinantly on this secondary system though we cannot at zygous mutant mice developed significantly more analpresent distinguish whether this novel ␦ system is ungesia than wild-type mice (Figure 3d) . masked or upregulated following DOR-1 ablation. We also explored the activity of DPDPE in the formalin Although the DOR-1 KO mice contained no observtest in DOR-1 KO mice. The appearance of the first and able To summarize, several lines of evidence indicate that DPDPE (8 g) given i.c.v. virtually eliminated the second a novel naltrexone-reversible mechanism which is not phase of the formalin response (Figure 4) . Thus, DPDPE blocked by subclass-specific opioid antagonists medianalgesic activity in the DOR-1 KO mice can also be ates retained DPDPE and deltorphin-2 analgesia, as well demonstrated in an analgesic model distinct from theras enhanced BW373U86 analgesia, in DOR-1 KO mice. mal nociception.
These include differential sensitivity to naltrindole, a We next chose to investigate in detail one of the deltaheightened response to BW373U86, and differential like responses-i.c.v. DPDPE analgesia-exhibited by sensitivity to an exon 3 oligonucleotide that does not DOR-1 mutant mice. We first explored the sensitivity of suppress DPDPE analgesia in DOR-1 KO as it does in the retained i.c.v. DPDPE analgesia to opioid receptor wild-type mice. Based on these data, we suggest that antagonists. The residual supraspinal DPDPE analgesia ␦ analgesia in wild-type mice is mediated predominately was effectively blocked in all genotypes by naltrexone, through DOR-1 systems, consistent with its sensitivity a general opioid receptor antagonist (Figure 5a) , conto both naltrindole and antisense probes based upon firming that the analgesia is opioid in nature. Conversely, DOR-1. In contrast, an upregulated (or unmasked), secneither the -selective antagonist ␤-funaltrexamine ondary ␦ system is responsible for the residual ␦ analge-(␤-FNA) nor the -specific drug norbinaltorphimine (norsia in DOR-1 KO mice, which explains its insensitivity BNI) blocked DPDPE supraspinal analgesia in any group toward the same antisense probe and the distinct (Figure 5a ). As expected, the ␦-selective antagonist nalpatterns of response to both ␦ agonists (such as trindole (Portoghese et al., 1988) significantly reduced BW373U86) and antagonists (such as naltrindole), com-DPDPE analgesia in wild-type mice. However, although naltrindole partially reduced DPDPE analgesia in the pared with wild type. (Figures 7c and 7d) . In contrast to wildIn these mice, the ability to develop tolerance to both type animals, in which the analgesic response to a fixed morphine and DPDPE is also completely abolished, indimorphine dose was lost within 5 days, DOR-1 KO mice cating that an enkephalin-DOR-1 ligand-receptor sysfailed to demonstrate tolerance following daily administem is likely an integral component of the pathway ( Taken together, these studies provide genetic evidosing, cumulative dose-response curves revealed a dence for a unique role for ␦ receptors in the central significant 2.8-fold shift to the right of the morphine ED 50 in the wild-type mice. In contrast, the potency of morphine in the DOR-1 KO mice was unchanged following chronic morphine (Table 1) and thus was identical to that observed in naive, wild-type mice. These results confirm and extend in a genetic model the importance of DOR-1 in morphine tolerance implied by earlier studies in which morphine tolerance was blocked by either low doses of naltrindole, which selectively antagonized ␦ receptors (Hepburn et al., 1997) , or by antisense targeting of DOR-1 (Kest et al., 1996) . In both prior cases, however, the complete blockage of tolerance development that was evident in the DOR-1 KO model was not observed.
Since supraspinal DPDPE analgesia was exhibited by gous DOR-1 KO mice remained unchanged for at least 6 into ES cells by electroporation. ES cells were selected for homoloafter 10 days with a cumulative dose-response paradigm. Signifigous recombination by culture in medium containing G418 and 2 cance was determined by the lack of overlap of 95% confidence M gancyclovir on days 2-7 following electroporation. DNA exlimits. The shift in the wild-type mice was significant, while that of tracted from the selected clones was digested with KpnI and the knockout mice was not. The experiment was repeated twice. screened by Southern blotting using an external 0.6 kb HindIII-DraII fragment 3Ј to the region included in the targeting construct. Screen
